Our laboratory accelerates translational neuro-oncology research, combining genetics and tumor biology with a unique insight into the pressing clinical questions facing patients with malignant brain tumors. We use novel genetic sequencing methods and modeling to understand how cancer grows in the brain, inadvertently supported by native brain cells. We focus on translational targets identified from and validated with primary human tissue and cerebral spinal fluid whenever possible, as this most reliably reflects the human disease. These findings have led to novel diagnostic tools and clinical trials for patients with malignant brain tumors. Our laboratory is a unique and collaborative working environment, engaged in the dynamic research environment at Stanford. Our laboratory space lies at the heart of the Stanford campus between the core campus and the medical facilities, emblematic of the translational aspects of our work.
Single-Cell RNA-Seq Analysis of Infiltrating Neoplastic Cells at the Migrating Front of Human Glioblastoma
Cell Reports. 2017 Oct 31; 21(5):1399-410.
Glioblastoma (GBM) is the most common primary brain cancer in adults and is notoriously difficult to treat because of its diffuse nature. We performed single-cell RNA sequencing (RNA-seq) on 3,589 cells in a cohort of four patients. We obtained cells from the tumor core as well as surrounding peripheral tissue. Our analysis revealed cellular variation in the tumor's genome and transcriptome. We were also able to identify infiltrating neoplastic cells in regions peripheral to the core lesions. Despite the existence of significant heterogeneity among neoplastic cells, we found that infiltrating GBM cells share a consistent gene signature between patients, suggesting a common mechanism of infiltration. Additionally, in investigating the immunological response to the tumors, we found transcriptionally distinct myeloid cell populations residing in the tumor core and the surrounding peritumoral space. Our data provide a detailed dissection of GBM cell types, revealing an abundance of information about tumor formation and migration.
Read more at:
Explore data at:
A survey of human brain transcriptome diversity at the single cell level.
PNAS | June 9, 2015 | vol. 112 | no. 23 | 7285–7290
The human brain is a tissue of vast complexity in terms of the cell types it comprises. Conventional approaches to classifying cell types in the human brain at single cell resolution have been limited to exploring relatively few markers and therefore have provided a limited molecular characterization of any given cell type. We used single cell RNA sequencing on 466 cells to capture the cellular complexity of the adult and fetal human brain at a whole transcriptome level.
Read more at:
Purification and Characterization of Progenitor and Mature Human Astrocytes Reveals Transcriptional and Functional Differences with Mouse.
Neuron | January 2016 | Volume 89, Issue 1, 6 | Pages 37–53
The functional and molecular similarities and distinctions between human and murine astrocytes are poorly understood. Here, we report the development of an immunopanning method to acutely purify astrocytes from fetal, juvenile, and adult human brains and to maintain these cells in serum-free cultures.
Read more at:
New tools for studying microglia in the mouse and human CNS.
Proc Natl Acad Sci U S A. 2016 Mar 22;113(12)
Here, we identify transmembrane protein 119 (Tmem119), a cell-surface protein of unknown function, as a highly expressed microglia-specific marker in both mouse and human. We developed monoclonal antibodies to its intracellular and extracellular domains that enable the immunostaining and isolation of microglia. Using our antibodies, we provide, to our knowledge, the first RNAseq profiles of highly pure mouse microglia during development and after an immune challenge.
Read more at:
Chromosome-scale mega-haplotypes enable digital karyotyping of cancer aneuploidy.
Nucleic Acids Research. 2017 Aug 16.
Genomic instability is a frequently occurring feature of cancer that involves large-scale structural alterations. These somatic changes in chromosome structure include duplication of entire chromosome arms and aneuploidy where chromosomes are duplicated beyond normal diploid content. However, the accurate determination of aneuploidy events in cancer genomes is a challenge. Recent advances in sequencing technology allow the characterization of haplotypes that extend megabases along the human genome using high molecular weight (HMW) DNA. For this study, we employed a library preparation method in which sequence reads have barcodes linked to single HMW DNA molecules. Barcode-linked reads are used to generate extended haplotypes on the order of megabases. We developed a method that leverages haplotypes to identify chromosomal segmental alterations in cancer and uses this information to join haplotypes together, thus extending the range of phased variants. With this approach, we identified mega-haplotypes that encompass entire chromosome arms. We characterized the chromosomal arm changes and aneuploidy events in a manner that offers similar information as a traditional karyotype but with the benefit of DNA sequence resolution. We applied this approach to characterize aneuploidy and chromosomal alterations from a series of primary colorectal cancers.
Read more at:
Brain tumor mutations detected in cerebral spinal fluid.
Clin Chem. 2015 Mar;61(3):514-22.
Detecting tumor-derived cell-free DNA (cfDNA) in the blood of brain tumor patients is challenging, presumably owing to the blood-brain barrier. Cerebral spinal fluid (CSF) may serve as an alternative "liquid biopsy" of brain tumors by enabling measurement of circulating DNA within CSF to characterize tumor-specific mutations. Many aspects about the characteristics and detectability of tumor mutations in CSF remain undetermined. We detected tumor mutations in CSF samples from 6 of 7 patients with solid brain tumors. The concentration of the tumor mutant alleles varied widely between patients, from <5 to nearly 3000 copies/mL CSF. We identified 7 somatic mutations from the CSF of a patient with leptomeningeal disease by use of cancer panel sequencing, and the result was concordant with genetic testing on the primary tumor biopsy. Tumor mutations were detectable in cfDNA from the CSF of patients with different primary and metastatic brain tumors. We designed 2 strategies to characterize tumor mutations in CSF for potential clinical diagnosis: the targeted detection of known driver mutations to monitor brain metastasis and the global characterization of genomic aberrations to direct personalized cancer care.
Read more at:
The "Liquid Biopsy": the Role of Circulating DNA and RNA in Central Nervous System Tumors.
Curr Neurol Neurosci Rep. 2016 Mar;16(3):25.
The detection of tumor-derived circulating nucleic acids in patients with cancer, known as the "liquid biopsy," has expanded from use in plasma to other bodily fluids in an increasing number of malignancies. Recent work suggests that cerebrospinal fluid may be a useful source of CNS tumor-derived circulating nucleic acids. In this review, we discuss the available data and future outlook on the use of the liquid biopsy for CNS tumors.
Read more at:
Tumor DNA in cerebral spinal fluid reflects clinical course in a patient with melanoma leptomeningeal brain metastases.
J Neurooncol. 2016 May;128(1):93-100.
In this report, we used droplet digital PCR to test mutant tumor DNA in CSF of a patient to monitor the treatment response of metastatic melanoma leptomeningeal disease (LMD). The mutant DNA fraction in CSF corresponded well with the patient's clinical response. We used whole exome sequencing to examine the mutation profiles of the LMD tumor DNA in CSF before therapeutic response and after disease relapse. The cellular and cfDNA revealed similar mutation profiles, suggesting cfDNA is representative of LMD cells.
Read more at:
J Clin Invest. 2018 Dec 3; 128(12): 5307–5321
DNA double-strand breaks (DSBs) are believed to be the most critical lesions induced by many cancer therapies, including chemotherapy and ionizing radiation (IR). Homology-directed repair (HDR), or homologous recombination repair, plays an important role in tumor resistance to treatment because it repairs these breaks. Hence, the clinical ability to inhibit HDR may lead to improved outcome for patients undergoing DSB-inducing cancer therapy. On the other hand, defects in HDR result in genomic instability and increase carcinogenesis, explaining the fact that tumor cells in many aggressive cancers, including some forms of breast, ovarian, and pancreatic cancers, are defective in HDR
Read more at:
Recurrently Mutated Genes Differ between Leptomeningeal and Solid Lung Cancer Brain Metastases.
J Thorac Oncology 2018 Jul;13(7):1022-1027.
When compared with solid brain metastases from NSCLC, leptomeningeal disease (LMD) has unique growth patterns and is rapidly fatal. Patients with LMD do not undergo surgical resection, limiting the tissue available for scientific research. In this study we performed whole exome sequencing on eight samples of LMD to identify somatic mutations and compared the results with those for 26 solid brain metastases.
Read more at:
Nature Medicine. 2019 Nov
Proinflammatory cytokines in the tumor microenvironment can promote tumor growth, yet their value as therapeutic targets remains underexploited. We validated the functional significance of the cardiotrophin-like cytokine factor 1 (CLCF1)-ciliary neurotrophic factor receptor (CNTFR) signaling axis in lung adenocarcinoma (LUAD) and generated a high-affinity soluble receptor (eCNTFR-Fc) that sequesters CLCF1, thereby inhibiting its oncogenic effects. eCNTFR-Fc inhibits tumor growth in multiple xenograft models and in an autochthonous, highly aggressive genetically engineered mouse model of LUAD, driven by activation of oncogenic Kras and loss of Trp53.
Read more at:
J Clin Invest. 2018 Dec 3;128(12):5307-5321
Linya, Lina, Candace, Ian, Sophia, Eli, Yingmei, Melanie
(from left to right)
Our team combines experience with passion, creativity, and dedication.
Melanie Hayden Gephart
Dr. Hayden Gephart did her residency and post doctoral training at Stanford University in neurosurgery and cancer biology. She joined as faculty in 2014 and is a brain tumor neurosurgeon.
Sophia is an experienced cancer biologist with a background in cell and molecular biology, protein biochemistry, assay development, biomarker discovery and drug development.
Shruti has obtained her PhD in Neuroscience from Kent State University, Ohio in 2017. She has extensive experience in developmental neurobiology and her PhD work was focused on local translation of mRNAs during brain development in Down syndrome. She enjoys traveling, painting and Zumba.
Bina is a Stanford medical student interested in neurosurgery. He completed his undergraduate degree in neuroscience and computer science at the College of William and Mary. He enjoys traveling, playing soccer, and experimenting with cooking different cuisines.
Hriday P. Bhambhvani
Hriday is a medical student at Stanford interested in neurosurgery. He received dual bachelor's degrees in neuroscience and mathematics from the University of Alabama at Birmingham in 2017. He enjoys playing soccer, hiking and writing.
Steffi is an undergraduate at Stanford. She has not declared her major but is interested in biology and computer science and is looking at potentially going to medical school. She enjoys playing soccer, skiing, and singing in her free time.
Maxine obtained her PhD in Biochemistry, Molecular, Cell and Developmental Biology with an emphasis in Translational Research from UC Davis. She has an extensive background in cancer biology and an interest in triple negative breast cancer, which has a higher incidence and death rate in African-American women. She enjoys volleyball, piano playing, analyzing data, and making pretty graphs.
Adrian John Rodrigues
Adrian is a Stanford medical student interested in neurosurgery. He completed his undergraduate degree in biology and economics at Yale. He enjoys hiking, playing tennis, and reading.
Clinical Research Coordinator
Monica Granucci is a Clinical Research Coordinator with the Cancer Clinical Trials Office and the Brain Tumor Center. She works to facilitate research tissue acquisition at Stanford, as well as assisting with the design, conduct, and management of some of Stanford’s Neurosurgery Department’s clinical trials.
Yuelong obtained his MD in neurosurgery from West China Hospital of Sichuan
University in 2017. He has an extensive background in brain tumor biology and an interest in brain tumor immunology and immunotherapy.
Bryanna is an undergraduate at Stanford. She is studying Human Biology with a concentration in neurodegenerative diseases and cancer. She hopes to pursue further studies in medicine or public health. She enjoys reading, cooking, and playing the flute in her free time.
Sam obtained his PhD in Cellular and Molecular Medicine from Johns Hopkins University, Baltimore in 2020. He has experience in developmental neurobiology and enjoys reading and hiking in his free time.
Crystal is a Stanford pediatric hematology/oncology fellow interested in translational oncology research. She went to medical school at Johns Hopkins University School of Medicine and completed her pediatrics residency training at St. Christopher's Hospital for Children in Philadelphia. She enjoys cooking and going to the beach.
Neuro-oncology research, it's personal
Neurosurgery isn't just my career and practice, it is a personal struggle to help improve the treatment for patients with brain tumors. These diseases have taken the lives of many of my friends and family, and affects the lives of my patients every day. Just a handful of their photos are listed here. We are committed to improving the care of patients with brain tumors and understanding the underlying mechanisms of disease progression, motivated by a personal understanding of the disease. I work in the operating room employing the maximal treatment for patients in my clinic today. The lab looks to develop new treatments and diagnostic techniques for the future patients who will be in the clinic tomorrow.
Robert Bean (1966 - 2000)
Robert Bean, Dr. Hayden's uncle, passed away at the age of 37 from Glioblastoma.
Paul Kalanithi (1977 - 2015)
Paul, Dr. Hayden's co-resident, was diagnosed with metastatic lung cancer during his neurosurgery residency. He passed away at the age of 37.
Position in the Lab (2013 - 2016): Graduate Student
Subsequent position Scientist at Grail Inc.
Position in the Lab (2015 - 2016): Post doctorate
Subsequent position: Shanghai Medical College of Fudan University
Position in the Lab (2014 - 2018): Post doctorate
Subsequent position: Scientist at BindeBio and Chinese Academy of Science.
Position in the Lab (2014 - 2019) : Medical Student
Subsequent position: Neurosurgery Resident Physician at Massachusetts General Hospital
Position in the Lab (2019 - 2019): Medical Student
Subsequent position: Neurosurgery student at Huashan Hospital, Fudan University.
Position in the Lab (2015 - 2020): Medical Student
Subsequent position: Neurosurgery Resident at Duke, University.
Position in the Lab (2019 - 2020): Post doctorate
Subsequent position: Scientist at Arsenal Bio.
SUPPORT OUR RESEARCH
A gift to the Gephart Lab will support our research on brain tumors.
If you would like to make a donation for this purpose, please contact:
Allie S. Gregorian
Medical Center Development
Interested in joining our team?
Please submit a CV with a brief description of your research interests and career goals to Melanie Hayden Gephart (firstname.lastname@example.org)
We are looking for a postdoctoral scientist to accelerate the study and targeting of malignant brain tumors using genetic tools and primary human samples. A competitive applicant for this position will have an interest in malignant brain tumors, neuroscience, and bioinformatics. Candidates must hold a Ph.D. from an accredited institution in a relevant research field, have strong laboratory, analytical, and organizational skills, and be able to work independently, as well as part of a team. Our work in the laboratory will enhance patient care through an improved understanding of malignant brain tumor biology.